Description
Ustekinumab is a monoclonal antibody medication developed by Janssen Pharmaceuticals. It is mainly used to treat psoriasis, Crohn’s disease, and ulcerative colitis. Janssen’s Ustekinumab, STELARA was approved for its first indication in China in November 2017 and was officially commercialized and sold in 2019. By 2020, Janssen-Cilag International NV (BE) is the only manufacturer in the Chinese Ustekinumab market.
According to CRI’s market research, after Ustekinumab entered the Chinese market, the sales increased from CNY0.6 million in 2019 to CNY 2.25 million in 2020. The annual growth rate is 274%
CRI analyzes that the sales of Ustekinumab will continue to increase in the next five years due to market expansion. After Ustekinumab was approved for its first indication in China in 2017, its second indication was approved in March 2020, which is used to treat moderate to severe active Crohn’s disease. With the approval of the new indication, sales will increase accordingly. Besides, Ustekinumab had four approved indications globally, which means the number of approved indications has the potential to expand in China, so the sales will keep increasing. On the other hand, the relatively high price for Ustekinumab results in suboptimal sales in China. Since Ustekinumab has only been in the Chinese market for a short period, Janssen is not enthusiastic about the national medical insurance negotiation. However, with the emergence of domestic biosimilar drugs in the future, the price for Ustekinumab is expected to decrease and the market will be further expanded.
Topics Covered:
-The impact of COVID-19 on China’s Ustekinumab market
– Sales value and volume of China’s Ustekinumab 2016-2020
– Competitive landscape of China’s Ustekinumab market
– Prices of Ustekinumab in China
– Prices of Ustekinumab in China by regions and manufacturers
– Analysis on factors affecting the development of China’s Ustekinumab market
– Prospect of China’s Ustekinumab market from 2021 to 2025
Table of Contents
1 Relevant Concepts of Ustekinumab
1.1 Indications for Ustekinumab
1.2 Development of Ustekinumab in China
1.3 Governmental Approval of Ustekinumab in China
1.4 The Impact of COVID-19 on Ustekinumab sales in China
2 Sales of Ustekinumab in China, 2019-2020
2.1 Sales Value of Ustekinumab
2.1.1 Overall Sales Value
2.1.2 Sales Value by Region
2.2 Sales Volume of Ustekinumab
2.2.1 Overall Sales Volume
2.2.2 Sales Volume by Regions
2.3 Sales of Ustekinumab by Dosage Form in China, 2019-2020
2.3.1 Injection
2.3.2 Analysis of Other Dosage Forms
3 Analysis of Major Ustekinumab Manufacturers in China, 2019-2020
3.1 Analysis of Market Share of Major Ustekinumab Manufacturers
3.1.1 Investigation on Market Share by Sales Value
3.1.2 Investigation on Market Share by Sales volume
3.2 Janssen-Cilag International NV (BE)
3.2.1 Enterprise Profile
3.2.2 Sales of STELARA (Janssen’s Ustekinumab) in China
4 Prices of Ustekinumab for Different Manufacturers in China, 2020-2021
4.1 Janssen-Cilag International NV (BE) (STELARA)
5 Prospect of Chinese Ustekinumab drug Market, 2021-2025
5.1 Influential Factors of Chinese Ustekinumab Market Development
5.1.1 The Impact of COVID-19 on Chinese Ustekinumab Market
5.1.2 Market Drivers and Opportunities
5.1.3 Market Threats and Challenges
5.2 Forecast on Market Size
5.3 Forecast on Market Trend
List of Charts
Chart Patent Information About Ustekinumab Injection Registration in China
Chart Sales Value of Ustekinumab Injection over the World
Chart Sales Value of Ustekinumab Injection in China, 2019-2020
Chart Sales Value of Ustekinumab Injection in China by Regions, 2019-2020
Chart Sales Volume of Ustekinumab Injection in China, 2019-2020
Chart Sales Volume of Ustekinumab Injection in China by Regions, 2019-2020
Chart Market Share by Sales Value of Top Ustekinumab Manufacturers in China, 2019-2020
Chart Sales Value and Volume of STELARA in China, 2019-2020
Chart Referential Prices of STELARA in China, 2020-2021
Chart Forecast on Sales Value of Ustekinumab in China, 2021-2025
Chart Forecast on Sales Volume of Ustekinumab in China, 2021-2025
